首页
Top Medical News
6 days ago
Erectile dysfunction and low testosterone levels are tied to life dissatisfaction in men with spinal cord injury, a recent study has shown.
27 Apr ck棋牌
A bidirectional relationship exists between nocturia and depressive symptoms, a recent study has shown.
26 Apr ck棋牌
Intravesical gemcitabine and docetaxel is an effective and well-tolerated rescue therapy, delivering a durable response in patients with recurrent nonmuscle invasive bladder cancer and a history of bacillus Calmette-Guérin treatment, a recent study has shown.
Christina Lau, 21 Apr ck棋牌

Prostate-specific membrane antigen (PSMA) PET-CT offers superior accuracy in identifying pelvic nodal or distant-metastatic disease in men with high-risk prostate cancer and may be a suitable replacement for conventional imaging with CT combined with bone scan, according to results of the proPSMA study.

20 Apr ck棋牌
Individuals who develop stones prior to age 20 years are at high risk of having frequent recurrences, with the risk even more pronounced in women, a study has found.
14 Apr ck棋牌
Use of double internal stents (DIS) in the long term offers durable relief in patients with secondary extrinsic malignant ureteral obstruction (EMUO), reveals a study. DIS avoids the use of external tubes and improves quality of life, making it a valuable alternative to other methods of urinary diversion.
12 Apr ck棋牌
A study in Japan has revealed an association between severe insulin resistance and kidney stone formation under normoglycaemic conditions.
Special Reports
26 Nov 2019
The incidence of prostate cancer (PC) and cardiovascular disease (CVD) typically increases with age; therefore, the choice of treatment for PC should take into account a patient’s underlying cardiovascular conditions. In this interview, Professor Laurence Klotz shared his take on androgen deprivation therapy (ADT) options for patients with prostate cancer who are at-risk of CV events.
15 Mar 2019
At the Eisai-sponsored tea symposium during the 27th Malaysian Urological Conference at Shangri-La Kuala Lumpur, Professor Osamu Yokoyama highlighted the advantages of silodosin (Urief®, Eisai Inc.) in relieving lower urinary tract symptoms associated with benign prostate hyperplasia.
Conference Reports
Audrey Abella, 23 Mar ck棋牌
The addition of the potent triple angiokinase inhibitor nintedanib to a standard chemotherapeutic regimen consisting of gemcitabine and cisplatin generated survival benefit in patients with locally advanced muscle invasive bladder cancer (MIBC), according to the results of the NEO-BLADE* trial presented at ASCO GU ck棋牌. However, the study failed to demonstrate improvement in the primary endpoint of pathologic complete response (CR).
Elaine Soliven, 14 Mar ck棋牌
The use of sipuleucel-T significantly prolongs overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), regardless of treatment setting, based on real-world data presented at ASCO GU ck棋牌.
Pearl Toh, 09 Mar ck棋牌
A combination therapy of enfortumab vedotin and pembrolizumab shows promising activity, with rapid and durable responses in the first-line setting for patients with metastatic urothelial carcinoma (mUC) ineligible to receive cisplatin, according to updates from the EV-103* study presented at GUCS ck棋牌.
Roshini Claire Anthony, 05 Mar ck棋牌

Patients with previously treated advanced or metastatic clear cell renal cell carcinoma (RCC) appear to derive greater overall survival (OS) benefit with nivolumab compared with everolimus, according to final results of the phase III CheckMate 025* trial presented at ASCO GU ck棋牌.

Audrey Abella, 03 Mar ck棋牌
An electronic surveillance tool generated better compliance and satisfaction rates than standard in-person care among men with stage 1 testicular cancer, according to the interim results of the WATChmAN* trial presented at ASCO GU ck棋牌.
Pearl Toh, 02 Mar ck棋牌
While combining docetaxel with androgen deprivation therapy (ADT) is known to improve survival for advanced prostate cancer, its role in the setting of adjuvant treatment given after radical radiotherapy plus ADT for the treatment of intermediate- and high-risk prostate cancer was proven otherwise — both in terms of biochemical disease-free survival (BDFS) and quality of life (QoL), according to the SPCG*-13 trial presented at the ck棋牌 Genitourinary Cancer Symposium (GUCS).
Roshini Claire Anthony, 29 Feb ck棋牌

The addition of apalutamide, a novel androgen receptor inhibitor, to androgen deprivation therapy (ADT) reduced the risk of progression while on first subsequent therapy or death (PFS2) in men with metastatic castration-sensitive prostate cancer (mCSPC), according to exploratory analysis of the phase III TITAN* trial.